CORona Drug InTEractions database
Increasing Host Cellular Receptor--Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection
Pei-Hui Wang, Yun Cheng
Abstract
The ongoing outbreak of a new coronavirus (2019-nCoV) causes an epidemic of acute respiratory syndrome in humans. 2019-nCoV rapidly spread to national regions and multiple other countries, thus, pose a serious threat to public health. Recent studies show that spike (S) proteins of 2019-nCoV and SARS-CoV may use the same host cell receptor called angiotensin-converting enzyme 2 (ACE2) for entering into host cells. The affinity between ACE2 and 2019-nCoV S is much higher than ACE2 binding to SARS-CoV S protein, explaining that why 2019-nCoV seems to be more readily transmitted from the human to human. Here, we reported that ACE2 can be significantly upregulated after infection of various viruses including SARS-CoV and MERS-CoV. Basing on findings here, we propose that coronavirus infection can positively induce its cellular entry receptor to accelerate their replication and spread, thus drugs targeting ACE2 expression may be prepared for the future emerging infectious diseases caused by this cluster of viruses.
Source: BioRxiv
Related molecules
Name | Synonyms | Genes |
---|---|---|
Angiotensin-converting enzyme 2 | ACE-related carboxypeptidase, ACE2 | ACE2 |
Target | Target affiliation | Drug | Type | Result |
---|---|---|---|---|
Target | Target affiliation | Drug | Type | Result |
Name | Synonyms | Genes | Origin |
---|---|---|---|
Name | Synonyms | Genes | Origin |
Name | Synonyms | PubChem | DrugBank | RCSB PDB | ATC |
---|---|---|---|---|---|
Name | Synonyms | PubChem | DrugBank | RCSB PDB | ATC |
Title | Authors | DOI | Source | Article type | Date |
---|---|---|---|---|---|
Title | Authors | DOI | Source | Article type | Date |
Title | Status | Phases | Start Date | Prim. Comp. Date | Comp. Date | First Post. Date |
---|---|---|---|---|---|---|
Title | Status | Phases | Start Date | Prim. Comp. Date | Comp. Date | First Post. Date |
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID. It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
- Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction
- Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target
- Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug
- Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication
- Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial